June 1, 2016

Glytec Presents Key Studies at the AACE 25th Annual Scientific and Clinical Congress

Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.

Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.

May 31, 2016

Computer Algorithms Managing Insulin Dosages Result in Better Glycemic Control

When insulin dosages are calculated using computer algorithms to reach target blood glucose levels, hospitalized patients are less likely to have episodes of low blood sugar and recover sooner from diabetic ketoacidosis than when insulin dosages are calculated without an algorithm.

Those were key findings from two multisite studies presented at the American Association of Clinical Endocrinologists meeting, held May 25-29 in Orlando, Florida. “Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and the studies’ principal investigator.

May 16, 2016

Orange Regional Medical Center Receives HIMSS Stage 7 Award Based Largely on Glytec’s Insulin Decision Support Solution

Our client, Orange Regional Medical Center, received a HIMSS Analytics Stage 7 Award based largely on its success implementing Glytec’s eGlycemic Management System® to support computer-based precision insulin dosing.

HIMSS Analytics® awarded Orange Regional Medical Center (ORMC), in Middletown, N.Y., with a Stage 7 Award. The award represents ORMC’s attainment of the highest level on the Electronic Medical Record Adoption Model (EMRAM)℠.

March 12, 2016

Hospital Admissions Slashed with Diabetes Software

The use of insulin management software in hospital emergency departments can decrease hospital admissions for diabetic ketoacidosis (DKA) by 45%, according to a new study.

Hospital admissions were reduced by starting patients on IV insulin using Glucommander, a cloud-based insulin management software system, according to a new study. The study, conducted by researchers at Eastern Virginia Medical School, was published in Diabetes Technology & Therapeutics.

March 8, 2016

Putting Epic’s EHR to Work: Hawaii Pacific Executives on the Intersection of Health IT & Quality

We started on this journey because we identified patients with diabetes and their comorbidities as top reasons for readmissions and longer length of stay.

These patients are also at higher risk for postoperative complications. We looked at how our system was managing hyperglycemia. We looked at glucose values for all of our patients. The EHR makes that possible. Looking at the data, I was quite concerned. We had a lot of patients with hyperglycemia. There have been a lot of conversations at the American College of Surgeons National Surgical Quality Improvement Program meetings about hyperglycemia. Starting from there, we found a program [Glytec] to integrate into our EHR — something that could help with hyperglycemia management.

February 10, 2016

New Study Demonstrates Effectiveness and Cost Savings of Glytec’s Cloud-Based Decision Support System to Treat Diabetic Ketoacidosis in the Emergency Department

Study leveraging Glytec’s Glucommander IV demonstrated a lower rate of admissions and future hospitalizations, resulting in a cost savings of $78,000 within 12 months.

Glytec, the pioneer and leader in providing innovative glucose decision support software solutions for effective diabetes management, is pleased to share the results of a study conducted in collaboration with Wake Forest Medical School, Eastern Virginia Medical School, and Sentara Healthcare. The study demonstrated intensive insulin therapy used in emergency departments (ED) is useful in treating patients with mild to moderate diabetic ketoacidosis (DKA), resulting in a lower rate of admissions and future admissions to the hospital along with significant cost savings.

November 3, 2015

Study of Glytec’s Glucommander in an Outpatient Setting Indicates Dramatic A1C Reductions

Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.

Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes. According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%.

October 5, 2015

Study: Insulin Dosing Platform Helped Reduce Post-Cardiac Surgery Complications

Intensive insulin therapy, with the help of a patient-specific IV insulin dosing platform, helped reduce post-cardiac surgery complications, according to a new study from Emory University.

A total of 302 patients were looked at after coronary artery bypass graft (CABG) surgery. Results demonstrated that providing more precise insulin dosing via the Glucommander IV led to improved glycemic control and a significant reduction in the rate of hypoglycemia, which is a common side effect of intensive insulin therapy in patients undergoing cardiac surgery.

September 29, 2015

New Study Demonstrates That Improvements in Glucose Control Reduced Complications After Heart Surgery

Study from Emory University published in Diabetes Care leverages Glytec’s Glucommander IV platform to evaluate the optimal level of glycemic control needed to improve outcomes.

Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, is pleased to share the results of the GLUCO-CABG trial conducted by Emory University, which demonstrated intensive insulin therapy resulted in a reduction in post cardiac surgery complications. Hyperglycemia is common in patients undergoing cardiac surgery, reported in 60-90 percent of patients with a known history of diabetes and in more than half of patients without diabetes.

June 8, 2015

Glytec Presents Several Research Studies at the ADA 75th Scientific Sessions

Data continue to validate the benefits of standardized glycemic management through computerized decision support for both IV and subcutaneous insulin dosing.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the American Diabetes Association 75th Scientific Sessions. The 75th Scientific Sessions, taking place from June 5-9th in Boston, are the premier venue for exchanging news and showcasing innovation to the diabetes community.

June 4, 2015

37 More Hospitals Elect to Strengthen Their Diabetes Management Programs with Glytec

Company continues dramatic growth driven by its unprecedented, proven results.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announces 13 additional health systems across the U.S. have recently selected the company’s eGlycemic Management System® (eGMS®). Collectively, they represent 37 new hospital implementations. eGMS® enables providers, payers, and patients to control glucose levels, and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

May 19, 2015

Glytec Presents Several Research Studies at the AACE 24th Annual Scientific and Clinical Congress

Leading industry experts present the benefits of automated glucose management for both IV and subcutaneous insulin dosing.

Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management System® (eGMS®) were selected as poster presentations at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress, which took place from May 13-17th in Nashville, Tennessee.

May 7, 2015

Studies Provide Additional Validation of the Benefits of Automated Glucose Management for Both IV and SubQ Insulin Dosing

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the International Hospital Diabetes Meeting (IHDM), taking place from May 8-9th in San Francisco. Hosted by the Diabetes Technology Society, the fifth annual IHDM conference will showcase the optimal use of future and current technologies for people with diabetes in both critical and non-critical care settings.

October 9, 2014

Woodridge Seeing Great Glycemic Results from Using Glucommander

As part of Mountain States’ Corporate Glycemic Initiative, they implemented Glucommander, a computerized insulin dosing software, to get a better handle on patient glucose levels.

The Mountain States psychiatric facility invariably has patients who need their blood sugar monitored, but people at Woodridge aren’t in the same clinically controlled environment as patients in most hospitals. They aren’t bed-bound with an IV in their arm, and nobody monitors exactly what, when and how much they eat. Thus, it’s harder to control their blood sugar levels.

September 30, 2014

These Algorithms Reduce Readmissions

Using glycemic management software that integrates with its EHR system, a Virginia hospital system has achieved a 79% improvement over the national average for hyperglycemia rates.

Doctors and nurses following the standard of care in hospitals aren’t just paying more attention to analytics. These days, the algorithm can be the cornerstone of superior care. Consider the tricky process of controlling the glycemic levels of patients with diabetes. At eight-hospital, Virginia-based Sentara Healthcare, this translates into a 79% improvement over the national average for hyperglycemia rates. These hospitals have achieved an overall hypoglycemia rate of 0.83 percent, which hospital officials says is a remarkable blended rate for IV and subcutaneous insulin therapy.

May 28, 2014

Glucose Management System Improves Standard of Care at Sentara

Hospitals have often had trouble managing patients with hyperglycemia and hypoglycemia. To help remedy that problem, Sentara Healthcare has ushered in a new standard of care in glucose management.

In 2008, Sentara saw several of its patients die due to poor management of their diabetes. There were several devastating events of prolonged hypoglycemia that resulted in permanent brain damage for patients, says Paul Chidester, M.D., vice president of medical affairs at the Va.-based Sentara Norfolk General Hospital within the health system. Sentara had reached a point when it knew it needed to do something to improve the care of its diabetes patients. “We sort of tolerated poor control of hyperglycemia and viewed episodes of hypoglycemia as a rite of passage of being in the hospital,” Chidester admits. [We said] poor control happens, just live with it. We then realized the negative impact that had on our patients, and decided that it had to change.”

May 22, 2014

Duke University School of Nursing Study Shows Major Tertiary Hospital Saves More Than 72 Minutes Per Nurse While Improving Clinical Outcomes Using eGlycemic Management System

Time and motion study poster presented during AACE shows increased efficiency in insulin management and improved rates of hyperglycemia and hypoglycemia.

Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster, “New Interfaces for eGlycemic Management System Saves Nursing Time and Improves Patient Outcomes: Time and Motion Nursing Study,” is based on a study that shows a reduction in nursing time and improvements in both patient outcomes and nurse satisfaction through the integration of Glytec’s eGlycemic Management System® (eGMS®).

May 16, 2014

E-Check of Sugar Aids in Inpatient Hypoglycemia Control

Electronic monitoring of blood sugar levels may diminish hypoglycemia and reduce length of stay in hospitalized diabetic ketoacidosis (DKA) patients, researchers reported here.

In one study, patients monitored with the Glucommander system reduced episodes of hypoglycemia by 56%, Joseph Aloi, MD, director of the Strelitz Diabetes Center at Eastern Virginia Medical School in Norfolk, and colleagues reported at the American Association of Clinical Endocrinologists meeting here. In a second study, they showed that the same system reduced the overall hospital length of stay by nearly 2 1/2 days in patients with diabetic ketoacidosis.

May 13, 2014

Glytec Announces Late Breaking Abstracts Accepted for Poster Presentations at American Association of Clinical Endocrinologists 23rd Annual Scientific & Clinical Congress

Conducted by researchers from Duke University School of Nursing, Piedmont Healthcare, Jackson Madison County General Hospital, Sentara Health System and Eastern Virginia Medical School, the poster presentations will highlight research results evaluating Glytec’s eGlycemic Management System® in three leading acute care hospitals.

Glytec, LLC, a clinical information technology company dedicated to the mission of improving insulin management and glycemic control, announced today that several late breaking abstracts featuring the company’s eGlycemic Management System have been accepted for poster presentations at the American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress, taking place from May 14 – May 18, 2014, in Las Vegas. The posters will be displayed from 9:30 a.m. to 1:00 p.m. on Saturday, May 17th in the General Poster Sessions in the exhibit hall. Presentations by the lead authors will occur from 9:45 a.m. to 11:00 a.m. on Saturday, May 17th.

Eastern Virginia Medical School Study Indicates Major Glycemic Improvement in Subcutaneous Basal Bolus Insulin Delivery Using eGlycemic Management System

Poster presented during AACE shows improved outcomes using Glytec’s subcutaneous insulin dosing solution versus traditional basal bolus insulin therapy.

Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster is based on results experienced by Sentara Healthcare during the first 30 days after using Glytec’s Glucommander™ SubQ to manage subcutaneous Basal Bolus Insulin (BBI) therapy. The poster was presented by Joseph Aloi, MD, clinical director of the Strelitz Diabetes Center at Eastern Virginia Medical School, during the Congress’s general poster session.